H19 and cancer: In the overall analysis, the lncRNA H19 rs217727 polymorphism was not found to be significantly associated with cancer risk in the allelic (A vs. G), dominant (AA + GA vs. GG), recessive (AA vs. GA + GG), or additive (AA vs. GG) genetic models [A vs. G, odds ratio (OR): 1.051, 95% confidence interval (CI): 0.913, 1.211, P = 0.490; AA + GA vs. GG, OR: 0.970, 95% CI: 0.802, 1.174, P = 0.755; AA vs. GA + GG, OR: 1.232; 95% CI: 0.968, 1.568, P = 0.090; AA vs. GG, OR: 1.156, 95% CI: 0.868, 1.541, P = 0.321].